NCT03398564

Brief Summary

Laparoscopic cholecystectomy is a widely employed procedure in ambulatory surgery. Pain after laparoscopic cholecystectomy arises significantly from port site incisions in the anterior abdominal wall. Innervation of the anterior abdominal wall is segmentally supplied by pain afferents in the plane of fascia between transversus abdominis and the internal oblique muscles. Opioids analgesia is used to control postoperative pain, but it carries the risk of increased nausea and vomiting, ileus and sedation that may delay hospital discharge. Several techniques have been tried as.neuroaxial narcotics, intraperitoneal lavage of local anesthetic and transversus abdominis plan (TAP) block and successfully reduced opioid use and improve postoperative analgesia. The ultrasound-guided erector spinae plan(ESP) block is a recently described technique which produces reliable unilateral analgesia at thoraco-lumbar dermatomes. ESP block carries the advantages of being simple, safe, easily recognizable by ultrasound, and a catheter can be threaded to extend the duration of analgesia. Few case series reported the efficacy of (US)-guided ESP blocks in reducing postoperative pain and opioids consumption. Because of that, the investigators aimed to test the hypothesis that US-guided ESP blocks can decrease opioid consumption during the first 24 h after of laparoscopic cholecystectomy in comparison with the conventional systemic analgesia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P50-P75 for not_applicable postoperative-pain

Timeline
Completed

Started Jan 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 29, 2017

Completed
12 days until next milestone

Study Start

First participant enrolled

January 10, 2018

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 12, 2018

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2018

Completed
Last Updated

December 26, 2018

Status Verified

October 1, 2018

Enrollment Period

11 months

First QC Date

December 29, 2017

Last Update Submit

December 21, 2018

Conditions

Keywords

Erecror Spinae Plan Blockpostoperative painLaparoscopic cholecystectomy

Outcome Measures

Primary Outcomes (1)

  • Morphine consumption

    It was calculated as equivalent morphine dose to the opioid analgesia consumed

    24 hours postoperatively.

Secondary Outcomes (4)

  • Quality of analgesia

    Every 2 hours for 24 hours postoperatively

  • The intraoperative fentanyl

    2 hours

  • equivalent morphine dose in the recovery unit (PACU)

    one hour

  • Erector spinae plan block complications

    24 hours postoperative

Study Arms (3)

Group I (Control)

PLACEBO COMPARATOR

ultrasound guided Bilateral Erector Spinae Plan Block using isotonic saline

Procedure: Erector Spinae Plan Block

Group II (ESP)

ACTIVE COMPARATOR

ultrasound guided Bilateral Erector Spinae Plan Block with bupivacaine 0.25%

Procedure: Erector Spinae Plan Block

Group III(OSTAP)

ACTIVE COMPARATOR

Ultrasound-guided bilateral oblique subcostal TAP block

Procedure: Oblique subcostal TAP

Interventions

The trocar site incision was done 15 minutes after the block in the three groups. The skin was disinfected with chlorhexidine solution, and the high-frequency transducer was isolated with a sterile disposable plastic cover and gel. The patient was placed in lateral position. A high-frequency linear ultrasound probe was placed longitudinally lateral to the T8 spinous process by 3 cm. After identification of the 3 muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle was introduced in a cephalo-caudal orientation. The needle tip was positioned fascial plane between rhomboid major and erector spinae muscles. Hydrodissection by 1-2 ml of normal saline to visualize the plan, then deposition of local anesthetic was done. A total of 20 mL of 0.25% bupivacaine was injected here. The same procedure was repeated on the other side.

Group I (Control)Group II (ESP)

ultrasound-guided bilateral oblique subcostal TAP block with bupivacaine 0.25% (20ml on each side)

Group III(OSTAP)

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • ASA I- II adult patients
  • years old
  • elective laparoscopic cholecystectomy
  • Body mass index (BMI) less than 35
  • Port sites at or above thoracic T 10 dermatome

You may not qualify if:

  • Allergy to amino-amide local anesthetics
  • Presence of coagulopathy
  • Local skin infection at the needle puncture sites
  • Preoperative chronic dependence upon opioid and NSAID medications
  • Liver or renal insufficiency
  • History of psychiatric or neurological disease
  • Deafness
  • previous open surgery that need the conversion of laparoscopic to open surgery or manipulations more than expected with more tissue trauma
  • American Society of Anesthesiologists (ASA) above Class II

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Al Jedaani group of hospitals

Jeddah, Meccah, 21462/7500, Saudi Arabia

Location

Related Publications (1)

  • Ibrahim M. Erector Spinae Plane Block in Laparoscopic Cholecystectomy, Is There a Difference? A Randomized Controlled Trial. Anesth Essays Res. 2020 Jan-Mar;14(1):119-126. doi: 10.4103/aer.AER_144_19. Epub 2020 Feb 3.

MeSH Terms

Conditions

Pain, Postoperative

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 29, 2017

First Posted

January 12, 2018

Study Start

January 10, 2018

Primary Completion

November 30, 2018

Study Completion

November 30, 2018

Last Updated

December 26, 2018

Record last verified: 2018-10

Locations